近期，以成人卫生护理用品为主业的可靠股份（SZ301009），深陷公司内部治理风波的旋涡。 《每日经济新闻》记者注意到，作为当事人，景乃权在相关议案中投出反对票，并称"公司解除理由荒 唐、肤浅且违法违规，是与大股东因工作事项产生不同意见而发起的解除，是对国内独董制度的严重挑 衅"。 指控升级：被指"特定股东利益代言人" 2026年2月12日，位于杭州市余杭区向往街1118号英国中心T6-28层的可靠股份会议室内，一场没有硝烟 的治理"暗战"被摆上台面。 2月23日，可靠股份发布公告称，公司第五届董事会第十七次（临时）会议以现场结合网络会议方式召 开，会议以5票同意、2票反对的表决结果，审议通过了《关于解除景乃权先生独立董事职务的议案》。 其中，董事鲍佳与独立董事景乃权两人对该议案投下反对票。 在相关解释中，可靠股份方面控诉景乃权已丧失独立性，沦为"特定股东利益代言人"，并在履职中存在 擅自离席、拉黑董秘等缺乏职业操守的行为。而反对方鲍佳则长文反击，直指本次解职系实控人、董事 长金利伟对景乃权"敢于直言、坚持原则"的恶意打击报复，甚至牵扯出此前公司违规关联交易遭浙江证 监局警示的治理旧账。 可靠股份在2026年 ...

以成人卫生护理用品为主业的可靠股份（SZ301009，股价13.04元，市值35.45亿元），深陷内部治理的旋涡。 2月23日，可靠股份公告称，公司第五届董事会第十七次（临时）会议以现场结合网络会议方式召开，会议以5票同意、2票反对的表决结果，审议通过了 《关于解除景乃权先生独立董事职务的议案》。其中，董事鲍佳与独立董事景乃权两人对该议案投下反对票。 图片来源：可靠股份公告 在相关解释中，可靠股份方面控诉景乃权已丧失独立性，沦为"特定股东利益代言人"，并在履职中存在擅自离席、拉黑董秘等缺乏职业操守的行为。而反对 方鲍佳则长文反击，直指本次解职系实控人、董事长金利伟对景乃权"敢于直言、坚持原则"的恶意打击报复，甚至牵扯出此前公司违规关联交易遭浙江证监 局警示的治理旧账。 《每日经济新闻》记者（以下简称"每经记者"）注意到，作为当事人，景乃权在相关议案中投出反对票，并称"公司解除理由荒唐、肤浅且违法违规，是与 大股东因工作事项产生不同意见而发起的解除，是对国内独董制度的严重挑衅"。 指控升级：从"拉黑董秘"到"为特定利益代言" 2月12日，位于杭州市余杭区向往街1118号英国中心T6-28层的可靠股份会议室内，一 ...

Core Viewpoint - Sujiao Technology (SZ300284) faces regulatory scrutiny due to violations in revenue recognition and delayed disclosure of information regarding its significant shareholders, raising concerns about its compliance and fundamental performance [1][2]. Financial Violations - The company inaccurately reported financial data for 2023 and 2024 due to certain surveying and design projects not meeting revenue recognition criteria, leading to misleading representations of its operational results [2]. - The financial head, Wang Renchao, was held primarily responsible for the lack of diligence in financial reporting [2]. Information Disclosure Issues - There was a significant delay in disclosing the relationships of over 5% shareholders Wang Junhua and Fu Guanhua with their respective spouses' asset management and fund products, violating timely disclosure obligations under the Growth Enterprise Market listing rules [2]. - This "patch-up" disclosure approach deprived the market of timely knowledge regarding changes in shareholder structure [2]. Regulatory Response - The dual penalties from the Shenzhen Stock Exchange and Jiangsu Securities Regulatory Bureau reflect a stringent requirement for compliance among Growth Enterprise Market companies, holding both the company and individual executives accountable [2]. - The regulatory actions signal a strengthened oversight on "hidden concerted action relationships" [2]. Internal Governance Recommendations - The company should restructure its internal control processes for revenue recognition, particularly for surveying and design projects, by establishing a dual confirmation mechanism involving milestone nodes and external evidence [3]. - A dynamic monitoring mechanism for shareholder and related party information should be implemented to prevent delays in disclosure [3]. - Given the backdrop of declining performance, the company must enhance the timeliness of its earnings forecast corrections to avoid compounding compliance and operational risks [3]. Future Outlook - If the company fails to leverage this opportunity for compliance restructuring, it may face a loss of investor trust and a downward shift in valuation [3]. - There is hope that Sujiao Technology can use this as a turning point to strengthen compliance while actively addressing industry cyclical challenges, providing investors with reliable and transparent decision-making information [3].

Core Viewpoint - The recent decision by the Nasdaq Hearing Committee allows SVA (Sinovac Biotech Ltd.) to maintain its listing status on the Nasdaq Global Market, contingent upon the timely submission of financial reports by May 11, 2026 [1][3]. Group 1: Listing Status and Financial Reporting - Sinovac has been granted a reprieve from delisting, needing to submit its annual financial report for the year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by May 11, 2026 [1][4]. - The company has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to meet the reporting requirements [1][5]. Group 2: Historical Context and Financial Performance - The delisting crisis began over two months ago when Sinovac received a delisting notice from Nasdaq due to its failure to submit the required annual report on time [4][5]. - Sinovac's financial performance has drastically declined since its peak in 2021, with revenues dropping by 92.30% in 2022 and 69.97% in 2023, and net profits decreasing by 98.66% and 187.75% respectively [7]. Group 3: Product Pipeline and Market Opportunities - Despite the decline in COVID-19 vaccine demand, Sinovac has a diverse product pipeline, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccine, with new products like the 23-valent pneumococcal polysaccharide vaccine recently approved [7]. - The company is also expanding into international markets, having secured a contract for influenza vaccines in Chile and obtaining WHO prequalification for some of its products [7]. Group 4: Internal Governance Issues - Sinovac has faced ongoing internal governance challenges, stemming from a power struggle between co-founders, which has led to significant operational disruptions and a history of stock trading halts due to governance failures [8]. - The company announced a substantial dividend plan of $7.448 billion, which could deplete over 70% of its cash reserves, raising concerns about its financial sustainability [8].

Group 1 - The core point of the article is that Sinovac Biotech Ltd. has received approval from the Nasdaq Hearing Committee to maintain its listing status on the Nasdaq Global Market, provided it submits its financial reports by May 11, 2026 [1][3] - The company must complete the submission of its annual financial report for the fiscal year ending December 31, 2024, and the interim financial report for the second quarter of 2025 by the specified deadline [4][5] - Sinovac has engaged Zhonghua Certified Public Accountants to conduct independent audits and is working collaboratively to expedite the audit and reporting process [1][4] Group 2 - Sinovac's delisting crisis began over two months ago when it received a delisting notice from Nasdaq due to its failure to submit the required annual report on time [4][6] - The company reported a significant increase in revenue and net profit in 2021, with total revenue reaching 135.487 billion yuan, a year-on-year increase of 3694.36%, and net profit of 59.212 billion yuan, a year-on-year increase of 7571.97% [6][7] - However, the demand for COVID-19 vaccines has sharply declined, leading to a significant drop in revenue and net profit in 2022 and 2023, with revenue decreasing by 92.30% and 69.97%, and net profit decreasing by 98.66% and 187.75% respectively [7] Group 3 - Sinovac has a diverse product pipeline, including vaccines for hepatitis A, influenza, varicella, and inactivated polio vaccine, with recent approvals for new products such as the 23-valent pneumococcal polysaccharide vaccine [7] - The international market is becoming a new growth area for Sinovac, with recent successes in obtaining WHO pre-certification for certain vaccines and winning exclusive bids for influenza vaccine orders in Chile [7] - Internal governance issues remain unresolved, with ongoing conflicts between management and significant shareholders affecting the company's stability and operations [7]

Group 1 - The core viewpoint of the articles highlights that Shikong Technology is expected to report a revenue of 325 million to 385 million yuan for the year 2025, but will continue to incur losses, with net profit projected between -290 million and -235 million yuan, marking five consecutive years of losses from 2021 to 2025 [1] - The company has faced challenges in recent years, attributing its poor performance to high fixed costs, changes in market demand, difficulties in accounts receivable collection, and organizational adjustments, which have led to increased expenses [1] - As of the reporting period, the company has signed 53 new projects with a total contract value of approximately 326 million yuan, reflecting a year-on-year decline of 14.91%, indicating significant pressure in market expansion and project acquisition [1] Group 2 - On January 16, the company was ordered by the Beijing Securities Regulatory Bureau to rectify multiple issues, including non-operating fund occupation by controlling shareholders, insufficient asset impairment provisions, improper accounting, and inadequate internal controls, which reveal significant vulnerabilities in internal governance and financial management [2] - The company needs to optimize its cost control, market expansion, project management, and internal governance to achieve a turnaround in performance amid intense market competition [2] - The future ability of the company to overcome its difficulties through effective reforms and management improvements remains to be seen [2]

Core Viewpoint - The internal conflict within Zhongjian Technology (中简科技) continues, primarily involving a lawsuit initiated by former General Manager Wen Yuefang against the company regarding governance issues and board decisions [2][6]. Group 1: Legal Proceedings - On January 9, 2025, Zhongjian Technology announced it received a "Notice of Response" regarding a lawsuit filed by former General Manager Wen Yuefang, which has been accepted by the Jiangsu Province Changzhou Intermediate People's Court but has not yet gone to trial [2]. - Wen Yuefang filed the lawsuit in May 2025, claiming that the procedures for board nominations, meetings, and voting violated the Company Law and the company's articles of association, seeking to annul two resolutions [2][7]. - The first-instance court ruled against Wen Yuefang's claims in November 2025, leading her to file an appeal in December 2025 [3][4]. Group 2: Company Operations and Management - Despite the ongoing legal issues, Zhongjian Technology stated that its daily operations and management remain normal and that the lawsuit does not significantly impact its ongoing business or financial status [5]. - The company emphasized its commitment to actively respond to the lawsuit and protect the rights of its shareholders [5]. Group 3: Background of the Conflict - The conflict stems from strategic and management disagreements between Wen Yuefang and another founder, Chairman Yang Yonggang, which became public after Wen was dismissed from her position in November 2024 [6]. - Wen Yuefang has been a significant figure in the company, having held various roles since its inception and being recognized in Forbes lists for her contributions to technology [5][6]. Group 4: Financial Performance - In the third quarter of 2025, Zhongjian Technology reported a revenue of 684 million yuan, representing a year-on-year increase of 28.46%, and a net profit attributable to shareholders of 290 million yuan, up 25.45% [7].

Group 1 - The core point of the article highlights the management changes at Lianbo Fund Management Co., with the resignation of Chief Compliance Officer Fang Fang and the ongoing labor dispute involving former Vice President Zhu Jianrong, raising concerns about internal governance and management culture [1][5][6] - Fang Fang, a seasoned compliance professional, will leave her position on December 31, 2025, for personal reasons, after approximately 21 months in the role [5][17] - The timing of Fang's departure coincides with the upcoming court hearing for Zhu Jianrong's labor dispute against the company, which is set for January 19, 2026, indicating potential internal conflicts [1][18] Group 2 - The interim Chief Compliance Officer will be Luo Dengpan, who also serves as the General Manager and has a strong background in finance and regulatory compliance [7][19] - Luo's dual role as General Manager and acting Chief Compliance Officer may create governance challenges, as these positions typically require independence and mutual oversight [19][20] - Lianbo Fund, established in September 2021, currently manages only four public funds with a total asset size of approximately 980 million yuan, placing it at the lower end of the public fund industry [9][21] Group 3 - The company has faced frequent changes in its executive team, which may distract from its focus on business development and could impact team morale and external partnerships [11][24] - The situation reflects broader challenges faced by foreign-owned public funds in China, particularly in adapting to a competitive environment while building a stable and resilient organizational structure [12][24]

Core Points - The company, formerly known as the "King of Vaccines," has received a delisting notice from NASDAQ due to failure to submit its annual report for the fiscal year ending December 31, 2024, by the extended deadline [1][3] - The company has engaged UHY LLP as its new independent auditor to expedite the submission of the 2024 annual report and is actively communicating with NASDAQ to request an extension and a hearing regarding the delisting [1][3] - The company asserts that its listing status will not materially affect its core business operations, which continue to function normally, including vaccine research, production, and supply [3] Company Governance Issues - The company has faced internal governance failures for years, leading to significant turmoil, including the resignation of its previous auditing firm and a prolonged stock suspension [6][10] - A special shareholders' meeting held on July 9 resulted in the removal of the existing board and the appointment of ten new members, including the return of founder Yin Weidong [6][9] - The new board's actions have been met with resistance from the current chairman, Li Jiaqiang, who claims the special meeting was illegal, further complicating the company's governance situation [6][8] Financial Matters - The company announced a substantial dividend plan totaling $7.448 billion, with an initial payment of $55 per share, which could deplete over 70% of its cash reserves [6][7] - The total market capitalization of the company's U.S. stock is currently only $390 million, raising concerns about the sustainability of such a large dividend payout [8]

Core Viewpoint - The company, Sinovac Biotech, has received a delisting notice from NASDAQ due to its failure to submit the annual report for the fiscal year ending December 31, 2024, by the extended deadline [1][2] Group 1: Delisting Notice and Response - On November 12, 2025, Sinovac received a delisting decision letter from NASDAQ's Listing Qualifications Department [1] - The company has engaged UHY LLP as its new independent auditor to expedite the submission of the 2024 annual report and restore compliance with listing rules [1] - Sinovac plans to request an extension for the annual report submission and will seek a hearing regarding the delisting matter [2] Group 2: Business Operations and Governance Issues - Sinovac stated that its U.S. listing status will not materially affect its core business operations, which continue normally, including vaccine research, production, and supply [3] - Internal governance issues have plagued the company for years, leading to a prolonged stock suspension and a precarious listing status [4][6] - A special shareholders' meeting held on July 9, 2023, resulted in the removal of the current board, with new members appointed, but faced resistance from the existing chairman [4] Group 3: Financial Matters - The company announced a $7.448 billion dividend plan, with an initial payment of $55 per share, which could deplete over 70% of its cash reserves [4] - The special cash dividend was distributed to legal shareholders, with significant amounts going to major stakeholders [5]